ConductScience.org, home

Paper26769332

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.

Bissonnette R and 10 others. J Dermatolog Treat, 2016. Cited by 66 papers, by iCite.

Cite this record

ConductScience Library. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. Papers, record 26769332. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26769332

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.
PubMed
Journal
J Dermatolog Treat
PubMed
Year
2016
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
66
iCite
Relative citation ratio, by iCite
2.28
iCite
Revised in PubMed
2018-12-02
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bissonnette RRobert
2Luchi MMonica
3Fidelus-Gort RRosanne
4Jackson SShawnta
5Zhang HHaifeng
6Flores RRobert
7Newton RRobert
8Scherle PPeggy
9Yeleswaram SSwamy
10Chen XXuejun
11Menter AAlan

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AzetidinesMajor topic
Isonicotinic AcidsMajor topic
PsoriasisMajor topic
Adult
Aged
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Janus Kinase 1
Male
Middle Aged
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 66 citations.

PMIDTitleJournalYearIn PapersSource
42396462JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases.Front Immunol2026https://conductscience.org/library/papers/42396462PubMed
42187316Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.J Eur Acad Dermatol Venereol2026https://conductscience.org/library/papers/42187316PubMed
39995941Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022.Heliyon2025https://conductscience.org/library/papers/39995941PubMed
39367521Infection risk with JAK inhibitors in dermatoses: a meta-analysis.Int J Dermatol2025https://conductscience.org/library/papers/39367521PubMed
39283290Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL).Future Oncol2024https://conductscience.org/library/papers/39283290PubMed
39119317Small Molecules in the Management of Psoriasis and Psoriatic Arthritis.Indian J Dermatol2024https://conductscience.org/library/papers/39119317PubMed
38892802Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition.J Clin Med2024https://conductscience.org/library/papers/38892802PubMed
38731900Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature.Int J Mol Sci2024https://conductscience.org/library/papers/38731900PubMed
38444845Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.Front Immunol2024https://conductscience.org/library/papers/38444845PubMed
38399292New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.Pharmaceutics2024https://conductscience.org/library/papers/38399292PubMed
38314280Janus kinase inhibitors modify the fatty acid profile of extracellular vesicles and modulate the immune response.Heliyon2024https://conductscience.org/library/papers/38314280PubMed
37927384JAK Inhibitors in Psoriatic Disease.Clin Cosmet Investig Dermatol2023https://conductscience.org/library/papers/37927384PubMed
37784164Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy.Cell Commun Signal2023https://conductscience.org/library/papers/37784164PubMed
37123059Recent advances in targeted therapy for pancreatic adenocarcinoma.World J Gastrointest Oncol2023https://conductscience.org/library/papers/37123059PubMed
36163193Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis.BMC Rheumatol2022https://conductscience.org/library/papers/36163193PubMed
35265634Novel Therapeutic Target(s) for Psoriatic Disease.Front Med (Lausanne)2022https://conductscience.org/library/papers/35265634PubMed
35096256Review on Novel Oral Therapies for Psoriasis.J Clin Aesthet Dermatol2021https://conductscience.org/library/papers/35096256PubMed
34848210The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions.J Allergy Clin Immunol2022https://conductscience.org/library/papers/34848210PubMed
34640327Role of Janus Kinase Inhibitors in Therapy of Psoriasis.J Clin Med2021https://conductscience.org/library/papers/34640327PubMed
34073410Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?Cancers (Basel)2021https://conductscience.org/library/papers/34073410PubMed

See all 38 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
JAK13716PubTator's text mininghttps://conductscience.org/library/genes/3716

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26769332

GET https://conductscience.org/api/papers/v1/26769332/cited_by?page=2